NCT05887843View on ClinicalTrials.gov

Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis

PHASE1TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 8, 2023

Primary Completion Date

September 8, 2023

Study Completion Date

September 8, 2023

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

Mometasone + Azelastine

Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril

DRUG

Mometasone Furoate

Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril

DRUG

Azelastine Hydrochloride

Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril

Trial Locations (1)

Unknown

Sandoz Investigational Site, Toronto

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT05887843 - Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis | Biotech Hunter | Biotech Hunter